Pranav Sharma

Pranav Sharma

Auto-generated profile, based on publicly available information

Pranav Sharma

Department of Urology, Texas Tech University Health Sciences Center, Lubbock, TX, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Translational Andrology and Urology
Verified
Journal Article
Open access
PDF file
LKLaura C. Kidd
Laura C. Kidd
SCSharon Chaing
Sharon Chaing
JCJuan Chipollini
Juan Chipollini
AGAnna R. Giuliano
Anna R. Giuliano
PSPhilippe E. Spiess
Philippe E. Spiess
PSPranav Sharma
Pranav Sharma
Penile cancer is a rare disease in the United States, but rates are increasing, causing concern. Several risk factors have been associated with the disease, including human papillomavirus (HPV) infection. Knowledge of HPV pathogenesis has led to the development of a vaccine, which has proven instrumental in reducing the incidence of female HPV-related cancers, but results in men have yet to be elucidated. Fortunately, rates of vaccination are up-trending in both males and females in the past several years. In addition, targeted therapies are the focus of several ongoing research efforts. Some of these therapeutics are currently in use, while several are in trials. With continued patient education and research, both treatment and prevention of HPV-related pre-malignant lesions and penile cancer will likely diminish.

1 August 2015 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
PSPranav Sharma
Pranav Sharma
KZKamran Zargar-Shoshtari
Kamran Zargar-Shoshtari
JCJamie T. Caracciolo
Jamie T. Caracciolo
MFMayer Fishman
Mayer Fishman
MPMichael A. Poch
Michael A. Poch
Philippe SpiessPhilippe Spiess
Philippe Spiess

1 November 2015 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
PSPranav Sharma
Pranav Sharma
RDRosa Djajadiningrat
Rosa Djajadiningrat
KZKamran Zargar-Shoshtari
Kamran Zargar-Shoshtari
MCMario Catanzaro
Mario Catanzaro
YZYao Zhu
Yao Zhu
Philippe SpiessPhilippe Spiess
Philippe Spiess

1 March 2022 in Research and Reports in Urology
Verified
Journal Article
Open access
PDF file
ECErin Choi
Erin Choi
JBJohn D Buie
John D Buie
JCJaime Camacho
Jaime Camacho
PSPranav Sharma
Pranav Sharma
WRWerner T.W. de Riese
Werner T.W. de Riese
Androgen deprivation therapy (ADT) has been the main management strategy for prostate cancer for more than eight decades, nowadays achieved commonly by administration of luteinizing hormone-releasing hormone agonists. ADT markedly suppresses androgen hormones with the long-term risks of adverse events such as muscle weakness, impairment of glucose and lipid metabolism, impotence, osteoporosis, and secondary fractures. Extensive research has provided significantly better insight into the dynamics of ADT including identification of the benefits of sequential and combination therapies. This has led to the development of new pharmaceutical ADT modalities. This review provides a general overview of the evolution of ADT in the context of the new emerging pharmaceutical ADT modalities so that clinicians and medical providers have a better understanding of personalizing the available ADT options with their different risk-benefit profiles.

1 February 2019 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
HPHannah Pham
Hannah Pham
HTHarrison Torres
Harrison Torres
PSPranav Sharma
Pranav Sharma

1 August 2016 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
KZKamran Zargar-Shoshtari
Kamran Zargar-Shoshtari
Philippe SpiessPhilippe Spiess
Philippe Spiess
ABAnders Berglund
Anders Berglund
PSPranav Sharma
Pranav Sharma
JPJulio M. Powsang
Julio M. Powsang
JDJasreman Dhillon
Jasreman Dhillon